THE EFFECT OF LOW-MOLECULAR-WEIGHT HEPARIN ON THE BIRTH WEIGHT IN 28 TO 34-WEEK PREGNANCIES COMPLICATED BY INTRAUTERINE GROWTH RESTRICTION.
DOI:
https://doi.org/10.66604/a5kjnf94Keywords:
Intrauterine growth restriction, heparin, LMWH, birth weightAbstract
Background: The use of low-molecular-weight Heparin (LMWH) in intra-uterine growth reduction (IUGR) is very common. However, its effect on the neonatal birth weight has not been studied in our context. This study aims to compare the mean birth weight of neonates receiving IUGR versus controls in females presenting with IUGR. Methods: This comparative cross-sectional study enrolled 100 women aged 18–40 years of parity <6 presenting during gestational age 28–34 weeks presenting with IUGR from, Department of Obstetrics and Gynecology, Pakistan Institute of Medical Sciences, Islamabad. After applying the selection criteria and obtaining approval, group 1 females were given LMWH, i.e., 0.2–0.4 mL by subcutaneous injection, along with parenteral nutrition, while in group 2, females received only parenteral nutrition, i.e., the control group. Then, females were followed up until delivery on a 15-day basis. At the time of delivery, the baby’s birth weight was recorded. Results: The mean age of women in group 1 was 30.10±5.48 years, and in group 2 was 29.06±4.48 years. Mean gestational age was 30.49±1.87 weeks. The mean birth weight of infants in group 1 was 2957.20±177.76 grams, and in group 2 was 2663.7±176.32 grams, with a p<0.0001. Conclusion: The mean birth weight of neonates receiving LMWH is higher compared to controls in females presenting with intrauterine growth retardation.
References
Villalaín C, Herraiz I, Akolekar R, Figueras F, Crispi F, Rizzo G et al. Clinical practice guidance for the management of fetal growth restriction: an expert review. J Matern Fetal Neonatal Med 2025;38(1):2526111. DOI: https://doi.org/10.1080/14767058.2025.2526111 DOI: https://doi.org/10.1080/14767058.2025.2526111
Zafar H, Naz M. Frequency of IUGR in pregnancy induced hypertension. J Univ Med Dent Coll 2012;3(2):8–13.
Jacobwitz M, Kapse K, Ngwa J, De Asis-Cruz J, Wu Y, Donofrio MT, et al. Placental and fetal in utero growth among fetuses with congenital heart disease. JAMA Netw Open 2025;8(4):e257217. DOI: https://doi.org/10.1001/jamanetworkopen.2025.7217 DOI: https://doi.org/10.1001/jamanetworkopen.2025.7217
Baroutis D, Koukoumpanis K, Tzanis AA, Theodora M, Rizogiannis K, Bairaktaris D, et al. Low-molecular-weight heparin in preeclampsia: effects on biomarkers and prevention: A narrative review. Biomedicines 2025;13(10):2337. DOI: https://doi.org/10.3390/biomedicines13102337 DOI: https://doi.org/10.3390/biomedicines13102337
Rajalakshmi AS, Murthy AA, Sree Lakshmi K. Maternal thrombophilia and intrauterine growth restriction: A review of current evidence and clinical implications. Endocr Metab Sci 2025;19:100274. DOI: https://doi.org/10.1016/j.endmts.2025.100274 DOI: https://doi.org/10.1016/j.endmts.2025.100274
Zhao P, Lu Y, Liu S, Zhang L, Chen C, Yang X. Evaluating the efficacy of low-molecular-weight heparin in managing umbilical artery thrombosis during pregnancy: does it offer therapeutic benefits? Front Med (Lausanne) 2025;12:1540685. DOI: https://doi.org/10.3389/fmed.2025.1540685 DOI: https://doi.org/10.3389/fmed.2025.1540685
Yu YH, Shen LY, Zou H, Wang ZJ, Gong SP. Heparin for patients with growth-restricted fetus: a prospective randomized controlled trial. J Matern Fetal Neonatal Med 2010;23(9):980–7 DOI:: https://doi.org/10.3109/14767050903443459 DOI: https://doi.org/10.3109/14767050903443459
Ephraums S, Dasgupta A, Korah S, Pasupathy D, Seeho S. A comparison of international clinical practice guidelines for postpartum venous thromboembolism prophylaxis. BMC Pregnancy Childbirth 2025;25(1):150. DOI: https://doi.org/10.1186/s12884-025-07246-3 DOI: https://doi.org/10.1186/s12884-025-07246-3
Shan D, Li T, Tan X, Hu YY. Low-molecular-weight heparin and preeclampsia - does the sword cut both ways? Three case reports and review of literature. World J Clin Cases 2024;12(9):1634–43. DOI: https://doi.org/10.12998/wjcc.v12.i9.1634 DOI: https://doi.org/10.12998/wjcc.v12.i9.1634
Sarmadi S, Mirzaian E, Nili F, Khalafrezaei F. Placental pathological findings and their association with maternal and fetal clinical outcomes: A cross-sectional study. Int J Reprod Biomed 2024;22(10):771–80. DOI: https://doi.org/10.18502/ijrm.v22i10.17662 DOI: https://doi.org/10.18502/ijrm.v22i10.17662
Cruz-Lemini M, Vázquez JC, Ullmo J, Llurba E. Low-molecular-weight heparin for prevention of preeclampsia and other placenta-mediated complications: a systematic review and meta-analysis. Am J Obstet Gynecol 2022;226(2S):S1126–44.e17. DOI: https://doi.org/10.1016/j.ajog.2020.11.006 DOI: https://doi.org/10.1016/j.ajog.2020.11.006
Chen J, Huai J, Yang H. Low-molecular-weight heparin for the prevention of preeclampsia in high-risk pregnancies without thrombophilia: a systematic review and meta-analysis. BMC Pregnancy Childbirth 2024;24(1):68. DOI: https://doi.org/10.1186/s12884-023-06218-9 DOI: https://doi.org/10.1186/s12884-023-06218-9
Zhang Y, Guo S, Xu J. Multifunctional applications and research advances of low-molecular-weight heparin. Front Pharmacol 2025;16:1585762. DOI: https://doi.org/10.3389/fphar.2025.1585762 DOI: https://doi.org/10.3389/fphar.2025.1585762
Singh KK, Gupta A, Forstner D, Guettler J, Ahrens MS, Prakasan Sheeja A, et al. LMWH prevents thromboinflammation in the placenta via HBEGF-AKT signaling. Blood Adv 2024;8(18):4756–66. DOI: https://doi.org/10.1182/bloodadvances.2023011895 DOI: https://doi.org/10.1182/bloodadvances.2023011895
Kleijer ME, Dekker GA, Heard AR. Risk factors for intrauterine growth restriction in a socio-economically disadvantaged region. J Matern Fetal Neonatal Med 2005;18(1):23–30. DOI: https://doi.org/10.1080/14767050500127674 DOI: https://doi.org/10.1080/14767050500127674
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Qurat Ul Ain, Komal Imtiaz, Maria Nawaz (Author)
This work is licensed under a Creative Commons Attribution-NoDerivatives 4.0 International License.
All articles and/or materials are published under the CC BY-ND 4.0 International License, which permits sharing and redistribution in any medium or format, provided the work remains unchanged and is correctly attributed to the original authors and MedPulse Spectrum.
